CJC-1295 (without DAC)
Tetra-substituted GHRH(1–29) amide analogue (also called modified GRF 1–29), used in GHRH-receptor research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-CJCND-5 · ≥99% (see COA) · Lyophilised powder
Note: Salt form (e.g. acetate or TFA) and net peptide content to be confirmed from the supplier COA.
CJC-1295 (without DAC) overview
CJC-1295 without DAC is a 29-residue analogue of growth-hormone-releasing hormone (1–29) amide, with D-Ala2, Gln8, Ala15 and Leu27 substitutions intended to improve stability against enzymes. It is supplied as a lyophilised solid for in-vitro laboratory research.
CJC-1295 (without DAC) research background
Evidence status: Little peer-reviewed research is publicly available for this compound. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- 'CJC-1295 without DAC' (sometimes called modified GRF(1–29)) is a tetra-substituted GHRH(1–29) analogue without the albumin-binding complex. Little peer-reviewed research is publicly available for this compound. The published CJC-1295 human studies concern the DAC (albumin-binding) version and cannot be assumed to apply [1][2].
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
- GHRH-receptor agonism is expected from its design. No peer-reviewed pharmacology specific to this analogue was identified.
Research areas & model types
| Research area | Model type | Summary |
|---|---|---|
| CJC-1295 with DAC (context only) | Human (healthy adults) | [1] |
Human clinical research status
- No clinical studies of this specific analogue were identified. It is not an approved medicine.
Safety observations reported in studies
- No dedicated safety data were identified.
Known limitations
- Its identity should be confirmed from the COA (sequence substitutions).
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- No credible peer-reviewed hypotheses specific to this analogue were found.
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683 · doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PubMed 17018654 · doi:10.1210/jc.2006-1702
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
CJC-1295 (without DAC) / Ipamorelin blend
AOD9604
CJC-1295 (with DAC)
IGF-1 LR3
Browse similar compounds: Endocrine & receptor-signalling research peptides or the full catalogue.